We Empower Precision Medicine

Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY® System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, and clinical research. We are dedicated to enabling clinical laboratories worldwide to deliver affordable targeted genomic testing. Our advanced platform provides timely, accurate, and actionable results, improving clinical decision making and laboratory economics. Agena Bioscience is headquartered in San Diego, CA, and markets its products in over 30 countries worldwide through direct sales offices in Germany, China, and Australia, and through an extensive network of distributors.

www.agenabio.com

ARCEDI is a Danish biotech company, focused on the isolation of rare cells from the blood stream with applications in noninvasive prenatal testing (NIPT) and cancer. The company has a proprietary technology of enriching and isolating fetal cells from maternal blood and has developed the world’s first cell-based non-invasive prenatal test for fetal screening. Based on the proprietary technology, Arcedi has launched the “EVITA TEST COMPLETE”, a fetal cell-based non-invasive prenatal test (cbNIPT), which gives pregnant women in the gestational age of 10 to 14 weeks the opportunity of knowing the genetic status of the unborn child without the need for invasive tests. “EVITA TEST COMPLETE”, serves as a high-resolution alternative to cell-free NIPT, and based on simple blood sampling, holds the potential to replace the current invasive procedures, known to carry a slight risk of unintended abortions, and unnecessary stress and anxiety.

This proprietary technology of isolating and analyzing rare fetal cells from blood circulation will now lay the foundation for expansion into isolation and genetic testing on circulating tumor cells.

Bayer AG is a Life Science company active in the fields of pharmaceuticals and agriculture. With more than 7,000 employees in R&D, Bayer Pharmaceuticals focuses on the development of innovative therapies in Oncology, Cardiovascular Diseases and Women’s Health Care indications and reached 17.962 billion Euros in 2019. The Oncology branch has a diversified portfolio of drugs targeting oncogenic signaling, immune checkpoints as well as radio pharmaceuticals.

Following the motto “Science for a better life”, collaboration with academic and industrial partners is at the heart of Bayer’s R&D approach. The company is involved in multiple projects within the European Public-Private-Partnership Innovative Medicines Initiative (IMI) and held the EFPIA lead for the liquid biopsy technology evaluation consortium CANCER-ID, which is the predecessor of ELBS. Bayer is also part of the International Liquid Biopsy Alliance (ILBA) established by the FNIH.

Clinomics Europe has been established in Budapest in 2021 as the first EU subsidiary of Clinomics Inc, Korea. Our innovative, multiomics-based medical biotech company places its main focus on precision medicine and oncology. We develop novel molecular diagnostic tools based on cutting-edge technologies such as liquid biopsy, NGS (next-generation sequencing), real-time qPCR, dPCR, and more.

Minimally invasive and repeatable techniques such as liquid biopsy have significant advantages compared to gold-standard methods in oncology, enabling early diagnosis, real-time prognosis, and longitudinal therapy monitoring. Blood-based biomarkers such as circulating tumor cells (CTCs) and cell-free DNA and RNA are gaining attention as more sensitive and specific alternatives to traditional biomarkers. Our proprietary technology, the CD-Prime Lab-on-a-Disc platform enables the enrichment of intact, unlabelled CTCs, as well as the plasma fraction containing ctDNA (circulating tumor DNA) and exosomes, maximizing the potential of liquid biopsy applications in oncology. By combining liquid biopsy with state-of-the-art molecular technologies, such as NGS, qPCR, and dPCR, we aim to take precision medicine to the next level.

Besides our core technology, we also provide a wide range of R&D services in our well-equipped laboratories, offering customized liquid biopsy-based solutions for specific research projects. We also offer a broad selection of laboratory instruments and reagents. Read more about the full range of our activities at our website.

Exact Sciences has been a global pioneer in detecting cancer earlier and guiding treatment decisions. Today we are a leading, global cancer diagnostics company with over 5.500 employees worldwide. Our common aim is to eradicate cancer -- and the suffering it causes -- with tests that help in preventing cancer, detecting it earlier, and guiding treatment to provide life-changing value to patients.

Building on the success of the Oncotype DX® and the Cologuard® tests, Exact Sciences is investing in its product pipeline to enable personalised care at all stages of the disease.

We serve patients in more than 90 countries and are rapidly building an even stronger international presence to bring our tests to patients around the world.

For more information on Exact Sciences, please visit the company’s website and follow us on Twitter, Facebook or LinkedIn

At Illumina, our mission is to improve human health by unlocking the power of the genome. An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS and microarray technologies are among the most trusted in the world. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants – and potentially transform the cancer care cycle.

Comprehensive genomic profiling (CGP) is a NGS approach that uses a single assay to assess hundreds of genes including relevant cancer biomarkers, as established in guidelines and clinical trials, for therapy guidance. CGP testing started from minimal amounts of FFPE tissue and is now leveraging liquid biopsy to facilitate sample collection while decreasing the need for invasive tissue biopsy procedures.

We’re committed to advancing and individualizing the way cancer will be identified and treated. We want to partner with you in helping propel progress in personalized oncology. Together we can work toward achieving our ultimate goal: to make discoveries that will make a life-changing difference to cancer patients and their loved ones.

LGC SeraCare Life Sciences is a leading in vitro diagnostic (IVD) manufacturer of clinical diagnostic quality solutions to the extended life science industry. We are committed to improving patient healthcare by offering products and services that support accurate and reliable diagnostic testing results. These include:

• Quality Controls (IQC), Linearity & Calibration Verification Kits
• Oncology and Reproductive Health Reference Materials
• Proficiency Testing (EQA) Schemes
• Biological Materials, Reagents
• IVD Assay Development
• Quality Assurance Programs

Our 200+ employees and our FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland support diagnostic professionals in laboratories across the globe. We partner with IVD developers, pharmaceutical, CRO and academic institutions to share our expertise and resources in clinical genomics, clinical chemistry, immunochemistry, serology, and molecular diagnostics. LGC SeraCare’s portfolio of Oncology and Reproductive Health -focused reference materials are designed and manufactured to meet the precision challenges of many NGS assays. Our industry reputation and credibility are founded on the high quality ground-truth RNA, ctDNA and genomic DNA-based reference materials which are NGS platform agnostic and used as positive sample controls in tumor profiling, immuno-oncology, liquid biopsy, NIPT and germline cancer assay workflows. We are passionately committed to go beyond. In collaboration with our customers, our people and with absolute quality, we make the exploration of science our mission to create a safer world.

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinicians, clinical researchers, and biopharmaceutical companies with access to unparalleled resolution in the study of cells and their molecular characterization.

The company is a pioneer in the field of circulating tumor cell (CTC) analysis, and its proprietary CELLSEARCH® CTC Test is the first and only clinically validated, FDA-‍cleared test for detecting and enumerating CTCs to aid physicians in managing patients with metastatic breast, prostate and colorectalcancer when used in conjunction with other clinical methods of monitoring. Clinical studies have shown that the presence of CTC in the peripheral blood, as detected by the CELLSEARCH® CTC Test, is associated with decreased progression-free survival and decreased overall survival in patients treated for metastatic breast, prostate or colorectal cancer. Evaluating CTC at any time during the disease allows assessment of patient prognosis and is predictive of progression-free survival and overall survival.

DEPArray™ PLUS (for Research Use Only) is an image-based digital cell-sorting and isolation platform that enables clinical researchers to study rare cells with single-cell precision. The integration of CELLSEARCH and DEPArray technologies provides the most comprehensive cell-based liquid biopsy workflow (for research use) for the enumeration, sorting, and molecular characterization of rare circulating tumor cells with single-cell precision.

The company also commercializes the Ampli1™ product line (for Research Use Only), providing best-in-class single-cell Whole Genome Amplification, along with related Quality Controls and Single-cell targeted sequencing panels.

Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.

We are a fully integrated life sciences company with a 46-year legacy, excelling in the development, manufacturing, and distribution of innovative immunoassay and molecular diagnostic products. Our commitment to providing accurate, fast, and simple solutions allows us to redefine life from discovery to diagnosis.

Our company is structured into two divisions:

Life Science Division: As a member of ELBS, this division offers commercial solutions for IVD manufacturers developing immuno and molecular assays. Notably, our eco-conscious lyophilized NGS library preparation kit and glycerol-free NGS enzymes highlight our dedication to sustainable product innovation.

Diagnostic Division: Focuses on Point-of-care automation.

We provide life science raw materials for tests spanning human, animal, plant, and environmental applications. Our expansion into liquid biopsy oncology assists IVD manufacturers in developing molecular assays that seamlessly integrate into patient care workflows – from diagnosis and monitoring to treatment selection.

Our technologies align with evolving oncology diagnostics, bringing testing closer to the patient and contributing to personalized healthcare trends. By offering products that can be transported and stored at ambient temperatures, we reduce the carbon footprint associated with traditional cold-chain logistics, demonstrating our commitment to sustainability.

At Meridian, we are dedicated to guiding our customers through transitions, with the ultimate aim of positively impacting patient care while promoting eco-friendly practices.

In 2015 Nonacus was founded with a singular purpose: to offer high quality, non-invasive, genetic testing. Based off the Latin term ‘non acus’ meaning ‘no needle’, Nonacus accurately symbolises the company’s mission- to move away from intrusive and sometimes risky diagnostic procedures, like tissue biopsies or amniocentesis, towards less invasive testing.

Formed by a dedicated group of biotechnology professionals, we understand the need for laboratories to continually deliver progress. This understanding forms the basis of all our products and drives our innovation, and we work closely with Hospitals, Research Institutes and Universities across the world to ensure that our products always keep the end-user at the forefront.

Today Nonacus offers non-invasive solutions for prenatal, oncology and constitutional genetics applications. In the oncology space, we have created a full liquid biopsy workflow: from robust pre-analytical products that maximise cfDNA yield, to targeted NGS panels underpinned by our novel and sensitive Cell3 Target technology. Our ultimate goal is to enable seamless, cost effective, cutting-edge cancer genomics and democratise cancer monitoring globally.

nRichDX® based in Irvine, California, is an emerging leader in preanalytical sample prep solutions for isolation of cfDNA, ctDNA, and other rare analytes. The patented Revolution™ Sample Prep System was engineered specifically for liquid biopsy applications. It is the first and only high-yield, IVD-labeled sample prep platform that can process a wide range of total sample volumes from 1 mL - 50 mL in a single magnetic bead-based extraction from blood, plasma, and urine samples in the company’s unique nRicher™ Cartridge. Unlike other methods, Revolution sample prep doesn’t require sample transfer steps or inefficient sample pooling. nRichDX helps solve one of precision medicine’s greatest problems – – inaccurate or incomplete diagnostic results for liquid biopsy-based molecular diagnostic tests, like NGS and ddPCR, due to insufficient analyte.

OneCell Diagnostics is on a mission to democratize precision cancer monitoring and testing to make cancer testing an Actionable, Accessible, and Affordable solution. We bring the power of Genomics data and Artificial Intelligence (AI) to healthcare. We intend to impact millions of cancer patients’ lives by providing high-quality precision therapy options to all needful patients worldwide. Explore more about us Visit www.onecelldx.com or write us at info@onecelldx.com

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The application field of liquid biopsies is one of the key focus areas driving QIAGENs product development initiatives to provide new innovative Sample to insight solutions. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide.

Quanterix is a leader and pioneer in ultrasensitive biomarker detection technology and solutions. Quanterix’ digital detection technology, Simoa®, is widely used for ultrasensitive blood-based biomarker testing and clinical diagnostic applications. Simoa enables researchers to detect and quantify critical biomarkers, even at ultra-low levels, in most common biofluid sample types. Besides providing the Simoa family of instruments and reagents for life sciences and clinical applications, Quanterix also has a well-established CLIA lab which has been providing clinical testing services with quick turnaround time (TAT) to academic customers and industrial partners.

• First of its kind ultrasensitive digital detection capabilities
• Detect and quantify biomarkers at femto- to atto-gram levels
• Biomarkers include proteins, nucleic acids, and extracellular vesicles (EVs)
• See results in record time with high throughput, fully automated option

For liquid biopsy applications, the ultrasensitive Simoa platform can be used for early disease detection, treatment response monitoring, as well as disease recurrence or minimal residual disease (MRD) monitoring. The types of biomarkers that Simoa has been used for include proteins, nucleic acids, and exosomes/extracellular vesicles (EVs). As there is an increasing interest in EV-associated biomarkers for various applications, Quanterix is now offering new solutions and tools that combine ultrasensitivity and workflow efficiency to enable groundbreaking EV biomarker research.

SAGA Diagnostics is a is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients. The company is commercializing unique technology platforms which are ultrasensitive and can measure circulating tumor DNA (ctDNA) to ~0.001% MAF, which is 100-1000-fold more sensitive and specific than competing methods. Our ultrasensitive technologies are also applicable to conventional tissue biopsies.

SAGAsafe® is a technology platform with patented chemistry which can be run on most dPCR instrument systems. It has its prime utility in detecting and measuring point mutations and indels and can be used to stratify patients, find patients eligible for therapy, monitoring therapy response and MRD, and detection of resistance mutations. The ultrasensitivity means finding more patients earlier. SAGAsafe is currently in a CE-IVD marking process, with the aim of having a menu of clinically relevant assays available for clinical use during 2020-21.

SAGAsign® is a method combining WGS on tumor tissue followed by monitoring ctDNA by personalized dPCR. In an automated fashion, a “fingerprint” of chromosomal rearrangements is selected and a SAGAsign fingerprint assay developed using our proprietary bioinformatics pipeline. We and others have shown chromosomal rearrangements are very stable over time. SAGAsign is ideal for determining tumor burden, monitoring therapy response, detecting MRD, and recurrence monitoring. Research programs and clinical trials benefit from the cost-effectiveness and short turnaround time and SAGAsign’s ultrasensitivity. SAGA is working with academia, hospitals, and biopharma in R&D projects and sells RUO and CE-IVD kits to laboratories.

ScreenCell is a French biotech dedicated to the isolation and characterization of circulating tumor cells (CTCs) from the blood of cancer patients. ScreenCell has a microfiltration technology that retains the CTCs since they are larger than other cells in the blood circulation. This technology is fast, easy to use, cost-effective, and does not need any machinery or expensive equipment to work with.

ScreenCell has two main kits. The ScreenCell Cyto kit is designed for cytological analysis. It can be used for CTC (single or cluster) enumeration and also for identifying informative antigens by immunostaining methods. The ScreenCell MB kit is dedicated to molecular biology analysis. This kit captures unaltered live CTCs, therefore, it can be used to extract high-quality DNA and RNA for downstream analysis. Moreover, since the cells are alive, they could be kept in 2D or 3D cultures for drug screening or biobanking purposes.

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDMTM, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of 800+ hospitals, laboratories, and biopharma institutions and a global footprint in over 75 countries. SOPHiA GENETICS is the creator of a global data pooling and knowledge-sharing platform that advances data-driven medicine. Our global platform allows healthcare professionals to leverage their expertise and work together around the world – unlocking the promise of data-driven medicine at scale.

We offer a cloud-based Software-as-a-Service platform — the SOPHiA DDM™ platform — that enables healthcare institutions to get quick, robust insights from their data. We apply our technology to diseases such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts.

SOPHiA comes from the Greek Σοφία, meaning wisdom. Our brandmark is our guiding visual icon that symbolizes an eye processing different types of data in order to generate insights, which is the pink dot on the ‘i'.

The SOPHiA GENETICS liquid biopsy solutions incorporate the company’s state-of-the-art proprietary algorithms and advanced genomic analyses, made possible with artificial intelligence (AI), to provide customers with expedited and streamlined insights that increase the ability of clinician researchers to practice precision medicine. The power of a decentralized network like the SOPHiA DDM™ Platform is that diverse data inputs are continuously added to the network to fuel and teach our artificial intelligence algorithms, helping to produce stronger data outputs across time.

We are pushing the boundaries of today’s liquid biopsy capabilities with our expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS’ liquid biopsy capabilities demonstrates the company’s commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes.

Our goal at SOPHiA GENETICS is to increase the use of data-driven medicine around the world and advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide.

Stilla Technologies is the digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s solutions include the industry’s first 7-color digital PCR system, providing biomedical researchers and clinicians the highest multiplexing and detection capacity on the market.

Tethis S.p.A., a diagnostic company based in Milan, aims to enable the exploitation of liquid biopsy multi-biomarkers analysis in clinical practice for precise cancer management by leveraging on its expertise in sample preparation and processing.

Introducing automation and standardization in the critical pre-analytical phase, Tethis provides the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction). Processing fresh blood in EDTA at the point of blood collection, it ensures the preservation of all clinically relevant information.

The company’s proprietary slides – Smart Bio Surface (SBS), thanks to their functionalized nanocoated surface, allow the spontaneous, immediate, and gentle adhesion of normally non-adherent cells, such as white blood cells (WBCs), with no chemicals, no special temperatures, no other treatment. WBCs adhere to SBS slides as a monolayer distributed on their whole active area. SBS slides, combined with the proprietary automated pre-analytical instrument See.d, allow to identify and characterize rare cells in blood, like CTCs, with unprecedented sensitivity, also in early-stage settings.

See.d prepares in a completely automated and gentle manner SBS slides with fixed WBCs as well as tubes with stabilized plasma without specialized operators nor preservatives: both contents are stable and can be easily stored for efficient logistics (i.e. internal analysis or shipment to central lab). Tethis technology makes both CTCs and cell-free content available for biomarkers detection from the same blood draw, enabling multi-omics applications.

Volition is a leading epigenetics company and aims to revolutionize the diagnosis and monitoring of life-altering diseases, through low-cost routine blood tests.

Our Nucleosomics™ technology isolates any abnormal circulating nucleosomes from the blood bloodstream or other bodily fluid for quantification and analysis.

Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and other diseases. These epigenetic changes can be detected before diseased cells become abnormal enough to show up in traditional biopsies, and long before the first symptoms are felt.

So how will our Nucleosomics™ technology make a difference?

It can be used for population screening, risk stratification, as a diagnostic aid, and for disease and treatment monitoring.

We aim to replace unpleasant, invasive, and often expensive screening and diagnostic tests with Nu.Q® blood tests, helping to save lives and to reduce overall health care costs.

You can use our assays to answer your clinical questions, such as measuring treatment efficacy, or on-target and off-target effects in drug development. Applications include biomarker discovery in oncology, inflammatory conditions, diabetes, and more.

Volition's research and development activities are centred in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

Vortex Biosciences has developed a “no touch” microfluidic chip technology which captures intact, label-free and pure circulating tumour cells (CTCs) from blood, with high yields. These CTCs can then be analysed using a range of downstream workflows that help characterise them. This will provide researchers and clinicians with access to critical insights from whole cancer cells that underpin one of the main causes of metastasis, treatment resistance and disease recurrence.

Vortex aims to transform cancer care through using circulating tumour cells (CTCs) to inform personalised therapy development, guide therapy selection and monitor cancer – ultimately enabling the use of CTCs in everyday clinical practice. We are building a CTC sample to answer service proposition targeted at biopharma to support the development of biomarker-driven personalised medicines.

Originally a spin-out from University of California, Los Angeles, Vortex is now headquartered in the UK, with operations in London and the Bay Area, US. Vortex has opened a new CTC Centre of Excellence at The London Cancer Hub’s Innovation Gateway, on the same site as the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. The new laboratory is in addition to Vortex’s existing facility in San Francisco, California.

Vortex is a portfolio company of EMVC. EMVC is a wholly owned subsidiary and the corporate finance and venture capital arm of NetScientific Plc (AIM:NSCI).